Washington is currently home to 1690 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Vancouver. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Comparison Neuromuscular Blockade Monitors
NCT05006807
Recruiting
The overall objective of this research is to evaluate different laboratory-built and commercially available sensors used to measure the effects of neuromuscular blocking drugs on neuromuscular function during surgery, by measuring evoked thumb twitch response to ulnar nerve stimulation (also known as "twitch monitoring"). The specific aim is to compare mechanomyography, which is the "gold standard" laboratory measurement to assess neuromuscular blockade, to the sensors used in commercially avail... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
09/18/2023
Locations: University of Washington Medical Center, Seattle, Washington
Conditions: Neuromuscular Blockade
Register for Updates
Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A
NCT04131036
Recruiting
The investigators propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A. Per current standard of care, most patients are on prophylactic FVIII replacement therapy intravenously several times weekly with a goal of keeping the trough \>1% FVIII. Recent phase 3 data suggest superior bleed protection with emicizumab prophylaxis every 1-2 weeks. It is the purpose of this study to longitudinally assess joint health and bone density over 3 years and to compar... Read More
Gender:
MALE
Ages:
16 years and above
Trial Updated:
08/31/2023
Locations: Washington Center for Bleeding Disorders at Washington Institute for Coagulation, Seattle, Washington
Conditions: Hemophilia A
Register for Updates
Reach Out and Read (ROR) in the Neonatal Intensive Care Unit (NICU) Study
NCT06002360
Recruiting
The goal of this clinical trial is to learn about the effects of the Reach Out and Read program on infants and their families in the neonatal ICU. The main goals of this study are: * To complete a needs assessment for literacy interventions in the NICU population through evaluating baseline home literacy scores. * To evaluate the effects of the ROR intervention on parental stress levels as assessed by the 6-question State-Trait Anxiety Index (STAI-6) * To evaluate the effects of the ROR interve... Read More
Gender:
ALL
Ages:
14 days and below
Trial Updated:
08/15/2023
Locations: University of Washington Medical Center NICU, Seattle, Washington
Conditions: Anxiety, Parent-Child Relations, Literacy
Register for Updates
The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis
NCT03631225
Recruiting
The goal of treating patients diagnosed with rheumatoid arthritis (RA) is to achieve remission or low disease activity and thereby prevent joint damage, loss of physical function, and disability. Optimal management requires regular assessment of disease activity, with treatment changes made as needed for optimal efficacy. Vectra is a blood serum test that looks at 12 biomarkers and produces a score on a scale of 1 to 100. The Vectra score has been shown to be the strongest predictor of risk for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: Arthritis Northwest, PLLC, Spokane, Washington
Conditions: Rheumatoid Arthritis (RA)
Register for Updates
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
NCT03547115
Recruiting
This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combination with venetoclax in subjects with relapsed or refractory AML
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/03/2023
Locations: Swedish Cancer Institute, Seattle, Washington
Conditions: Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
Register for Updates
Venetoclax and Lintuzumab-Ac225 in AML Patients
NCT03867682
Recruiting
The study is a multicenter, open label Phase I/II trial. 1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapsed/refractory AML. (Phase 1 portion) 2. To assess the percentage of patients with CR, CRh, or Overall Response (CR + CRh), up to 6 months after the start of treatment without receiving other AML therapies. (Phase 2 portion)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/02/2023
Locations: Fred Hutchinson Cancer Research Center, Seattle, Washington
Conditions: Acute Myeloid Leukemia, Relapsed Adult AML
Register for Updates
Extended Cold Stored Apheresis Platelets in Cardiac Surgery Patients
NCT05220787
Recruiting
This trial is being performed to evaluate the feasibility of the study protocol and to test the efficacy and safety of platelets stored at cold conditions (1-6°C) in 100% plasma for 10-14 days (CSP) in cardiac surgery patients who are actively bleeding and require platelet transfusion.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/26/2023
Locations: Swedish Medical Center - Cherry Hill, Seattle, Washington
Conditions: Hemorrhage, Platelets; Defect, Bleeding, Surgical Blood Loss
Register for Updates
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
NCT04791384
Recruiting
This is a multi-institutional, single arm, open label, Phase Ib/II study of abemaciclib in combination with elacestrant in patients with HR+/Her2- breast cancer metastatic to the brain. Patients may have received up to two prior lines of systemic chemotherapy for locally advanced or metastatic disease. There will be no limit on prior use of endocrine therapy including aromatase inhibitors, tamoxifen and fulvestrant, given a documented clinical benefit of elacestrant in this setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2023
Locations: Cancer Care Northwest, Spokane Valley, Washington
Conditions: Breast Cancer
Register for Updates
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
NCT03987763
Recruiting
This study is to evaluate the safety, the systemic exposure of halobetasol propionate (HP), and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-122 lotion in pediatric participants with moderate to severe plaque psoriasis.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/25/2023
Locations: Bausch Site 1, Spokane, Washington
Conditions: Psoriasis
Register for Updates
Psorcast Mobile Study
NCT05621369
Recruiting
The purpose of this study is to understand variation in the symptoms of psoriasis and psoriatic arthritis using simple, scalable smartphone-based measurements. This study uses an iPhone app to record these symptoms through questionnaires and sensors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2023
Locations: Sage Bionetworks, Seattle, Washington
Conditions: Psoriatic Arthritis, Psoriasis, Psoriatic Conditions, Dermatologic Disease, Rheumatologic Disease, Psoriatic Nail, Plaque Psoriasis, Joint Pain, Dactylitis
Register for Updates
Long COVID-19 and MAB Study
NCT05508295
Recruiting
This study will be observational only. It will provide real-world evidence generated from a representative and large-scale COVID patient base. The adoption, pilot testing and use of NIH PROs among viral tested patients with research purpose on long COVID will be unique and innovative. With the existing and proven scientific rigor, NIH PRO system will be adopted, then modified and tailored to form the long hauler specific, comprehensive instrument, helping generalize future knowledge regarding CO... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/22/2023
Locations: MultiCare Health System, Tacoma, Washington
Conditions: COVID-19
Register for Updates
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
NCT05303636
Recruiting
The primary objective of this study is to evaluate the impact of LF111 and drospirenone (DRSP) 3.5 mg chewable tablets on bone mineral density (BMD) at the lumbar spine after 12 months (13 medication cycles) of investigation in comparison to non-hormonal contraceptive methods. Secondary objectives include further evaluating the impact of LF111 and DRSP 3.5 mg chewable tablets on BMD and bone turnover after 12 months (13 medication cycles) in comparison to non-hormonal contraceptive methods and a... Read More
Gender:
FEMALE
Ages:
Between 14 years and 45 years
Trial Updated:
06/15/2023
Locations: Seattle Clinical Research Center, Seattle, Washington
Conditions: Change in Bone Mineral Density, Bone Loss
Register for Updates